| abstract |
REFERS TO COMPOUNDS OF FORMULA (I), WHERE R1 IS ARYL OR HETEROARYL; X IS -CO O SO2; R2 IS H OR LOWER RENT OPTIONALLY REPLACED; W IS -CR4-, -CH2CR4-, O N; R3 IS -CO-R7-, H, CYANE, ALKYL, HETEROCYCLYL, SULFONYL OR ARYL, OPTIONALLY SUBSTITUTED; R5 IS H, OH, AMINO, HETEROCYCLYL, LOWER ALKYL, OPTIONALLY SUBSTITUTED; R6 IS H, ALCOXY, ARYLOXY, ALCOXYCARBONYL, HETERARYLOXY, AMINOCARBONYL, AMONG OTHERS, OPTIONALLY SUBSTITUTED; CONSIDERING THAT IF W IS N, THEN R5 IS NOT OH OR AMINO; R6 IS NOT ALCOXI, ARALCOXI, HETEROARALCOXI, NOR AMINO. THE PREFERRED ARE: N- (1- {4- [2- (1-ACETYLAMINE-ETHYL) -1-ETHYL-1H-IMIDAZOL-4-IL} -BENZIL} -3-HYDROXY-PROPYL) -3-CHLORINE-4 - (2,2,2-TRIFLUORO-1-METHYL-ETHOXY) -BENZAMIDE, N- {1- [4- (8-BROMO-5-METHYL-IMIDAZOL [1,2-a] PYRIDIN-2-ILO) -BENCIL] -3-HYDROXY-PROPYL} -3-CYANE, 4-ISOPROPOXY-BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF MITOTIC KINESIN FOR WHICH THEY ARE USEFUL FOR THE TREATMENT OF CELLULAR PROLIFERATION DISEASES, SUCH AS CANCER, HYPERPLASIAS, RESTENOSIS, HYPERTROPHY, RESTENOSIS, CARDIAC INFLUENTIC HYPERTROPHY, INDE-FUNCTIONAL TRIALS |